RT Journal Article SR Electronic T1 Cost-effectiveness of digital therapeutics for essential hypertension JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.03.02.22271583 DO 10.1101/2022.03.02.22271583 A1 Akihiro Nomura A1 Tomoyuki Tanigawa A1 Kazuomi Kario A1 Ataru Igarashi YR 2022 UL http://medrxiv.org/content/early/2022/03/06/2022.03.02.22271583.abstract AB Background Hypertension increases the risk of cardiovascular and other diseases. Lifestyle modification is a significant component of nonpharmacological treatments for hypertension. We previously reported the clinical efficacy of digital therapeutics (DTx) in the HERB-DH1 trial. However, there is still a lack of cost-effectiveness assessments evaluating the impact of prescription DTx. This study aimed to analyze the cost-effectiveness of using prescription DTx in treating hypertension.Methods We developed a monthly cycle Markov model and conducted Monte Carlo simulations using the HERB-DH1 trial data to investigate quality-adjusted life-years (QALYs) and the cost of DTx for hypertension plus guideline-based lifestyle modification consultation treatment as usual (TAU), comparing DTx+TAU and TAU-only groups with a lifetime horizon. The model inputs were obtained from the HERB-DH1 trial, published or publicly available data, and expert assumptions. The incremental cost-effectiveness ratio (ICER) per QALY was used as the benchmark for cost-effectiveness. We performed probabilistic sensitivity analyses (PSAs) using the Monte Carlo simulation with 2 million sets.Results The DTx+TAU strategy produced 18.778 QALY and was associated with ¥3,924,075 ($34,122) expected costs, compared with 18.686 QALY and ¥3,813,358 ($33,160) generated by the TAU-only strategy over a lifetime horizon, resulting in an ICER of ¥1,199,880 ($10,434)/QALY gained for DTx+TAU. The monthly cost and attrition rate of DTx for hypertension have a significant impact on ICERs. In the PSA, the probability of the DTx arm being a cost-effective option was 87.8% at a threshold value of ¥5 million ($43,478)/QALY gained.Conclusions The DTx+TAU strategy was more cost-effective than the TAU-only strategy.Competing Interest StatementAkihiro Nomura, Kazuomi Kario, and Ataru Igarashi received consulting fees from CureApp, Inc. Akihiro Nomura was a co-founder of CureApp Institute. Tomoyuki Tanigawa is a chief medical officer of CureApp Inc.Funding StatementThe HERB-DH1 pivotal trial whose data we used in this study was sponsored by CureApp, Inc (Tokyo, Japan). Also, CureApp Inc had patents and distribution rights for the HERB Mobile prescription DTx system.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board approved the study protocol in Kanazawa University, Japan.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the present study are available from the corresponding author upon reasonable request.